Skip to main content
Fig. 3 | SpringerPlus

Fig. 3

From: The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis

Fig. 3

Network diagrams for incidence of any adverse events (a), any serious adverse events (b), and any treatment-related adverse events (c) at 12 weeks. AZA azelaic acid, bid twice daily, IVE ivermectin, MET metronidazole, OD once daily. Note: network diagrams for the incidence of burning/stinging, skin irritation, worsening of erythema, and worsening of rosacea at 12 weeks are available in the Additional file 1

Back to article page